GlassScriptPhysician profile
Kelty R Baker
NPI 1710090857
$228,783.28
in general payments reported to CMS, 2019-2025
42 companies · $7,844 in 2025
The $7,844 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $58K · 2021: $22K · 2022: $26K · 2023: $40K · 2024: $4,210 · 2025: $7,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $12K · Food and Beverage: $4,626 · Travel and Lodging: $2,621 · Education: $62.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,915.00 |
| Consulting Fee | $12,162.00 |
| Food and Beverage | $4,626.33 |
| Travel and Lodging | $2,621.04 |
| Education | $62.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $50,981.10 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $41,240.17 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $40,434.85 | 2022-2025 | Pomalyst, Reblozyl |
| Incyte Corporation | $34,679.26 | 2019-2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $20,735.89 | 2019-2025 | Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $18,962.98 | 2019-2024 | Iclusig |
| Eusa Pharma (US) LLC | $12,262.47 | 2019-2021 | |
| Genzyme Corporation | $3,695.86 | 2019-2025 | |
| Morphosys, US INC. | $1,490.77 | 2021-2023 | Monjuvi |
| Pfizer INC. | $708.21 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $288.07 | 2019-2024 | Ultomiris |
| Amgen INC. | $285.13 | 2019-2024 | Xgeva, Nplate, Kyprolis |
| Novartis Pharmaceuticals Corporation | $254.05 | 2019-2025 | |
| Pharmaessentia USA Corporation | $240.74 | 2023-2025 | Besremi |
| Agios Pharmaceuticals, INC. | $240.55 | 2019-2025 | Pyrukynd |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $236.63 | 2022-2025 | Ayvakit |
| Beigene USA, INC. | $219.22 | 2021-2024 | Brukinsa |
| Sobi, INC | $178.47 | 2022-2025 | |
| Secura Bio, INC. | $163.41 | 2022-2024 | Copiktra |
| Seagen INC. | $152.63 | 2019-2020 | |
| Janssen Biotech, INC. | $149.84 | 2019-2023 | Darzalex |
| Recordati_rare_diseases_inc. | $147.89 | 2024-2025 | Sylvant |
| Abbvie INC. | $122.80 | 2021-2025 | |
| Apellis Pharmaceuticals, INC. | $119.81 | 2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $113.91 | 2020-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $111.04 | 2019 | |
| Glaxosmithkline, LLC. | $92.44 | 2023-2025 | Ojjaara, Blenrep, Shingrix |
| Alnylam Pharmaceuticals INC. | $69.39 | 2019-2023 | Onpattro |
| Ge Healthcare | $69.23 | 2024 | |
| Medtronic, INC. | $56.31 | 2022 | |
| Cti Biopharma Corp. | $53.79 | 2022-2023 | Vonjo |
| Lilly USA, LLC | $42.91 | 2023-2024 | Jaypirca |
| Amag Pharmaceuticals, INC. | $26.17 | 2019 | |
| Karyopharm Therapeutics INC. | $21.95 | 2023 | Xpovio |
| Taiho Oncology, INC. | $21.71 | 2023 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.48 | 2019 | |
| Syndax Pharmaceuticals, INC. | $16.38 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $15.66 | 2019 | |
| Merck Sharp & Dohme LLC | $15.37 | 2019 | |
| Beone Medicines USA, INC. | $15.25 | 2025 | Brukinsa |
| Innate Pharma, INC | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelty Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.